Clinical outcomes after initial pseudomonas acquisition in cystic fibrosis.
about
Treatments for preventing recurrence of infection withPseudomonas aeruginosain people with cystic fibrosisCurrent and Emerging Therapies for the Treatment of Cystic Fibrosis or Mitigation of Its SymptomsPediatric Pulmonology year in review 2015: Part 4.Pseudomonas aeruginosa in vitro phenotypes distinguish cystic fibrosis infection stages and outcomesCoculture of Staphylococcus aureus with Pseudomonas aeruginosa Drives S. aureus towards Fermentative Metabolism and Reduced Viability in a Cystic Fibrosis Model.BPI-ANCA Provides Additional Clinical Information to Anti-Pseudomonas Serology: Results from a Cohort of 117 Swedish Cystic Fibrosis PatientsThe Dynamics of Disease Progression in Cystic Fibrosis.Early Childhood Risk Factors for Decreased FEV1 at Age Six to Seven Years in Young Children with Cystic Fibrosis.Change in Pseudomonas aeruginosa prevalence in cystic fibrosis adults over time.Impact of Sustained Eradication of New Pseudomonas aeruginosa Infection on Long-term Outcomes in Cystic Fibrosis.Clinical impact of Achromobacter xylosoxidans colonization/infection in patients with cystic fibrosis.Activity of Cysteamine against the Cystic Fibrosis Pathogen Burkholderia cepacia Complex.Assessment of serology and spirometry and the combination of both to complement microbiological isolation for earlier detection of Pseudomonas aeruginosa infection in children with cystic fibrosis.Perception of first respiratory infection with Pseudomonas aeruginosa by people with cystic fibrosis and those close to them: an online qualitative studyUnderstanding persistent bacterial lung infections: clinical implications informed by the biology of the microbiota and biofilmsPseudomonas aeruginosa and post-tracheotomy bacterial respiratory tract infection readmissions.The success of the different eradication therapy regimens for Pseudomonas aeruginosa in cystic fibrosis.Invasive Pulmonary Fungal Infections in Cystic Fibrosis.A five-year retrospective analysis of adherence in cystic fibrosis.Editorial Commentary: Pseudomonas aeruginosa Eradication: How Do We Measure Success?Early-Life Pseudomonas aeruginosa Infection in Cystic Fibrosis and Lung Disease Progression.Understanding Pseudomonas status among adults with cystic fibrosis: a real-world comparison of the Leeds criteria against clinicians' decision.Longitudinal development of initial, chronic and mucoid Pseudomonas aeruginosa infection in young children with cystic fibrosis.
P2860
Q26470661-CDEB0DCA-5C35-4898-96D9-0872F12D6544Q28077411-D7CD6BA4-CF0B-4F10-99D5-ACDC5F6E5A09Q30250335-E19A24B3-66BF-499F-8F8A-6F4EBDAADB7DQ34480377-21D5C6B2-1D23-4226-8CDD-5FE4416B0EDDQ35914177-D62D5326-C38B-4A86-8D5A-28F7BBA471D1Q35931148-9975E2A7-F7E3-42C4-9C91-F87C0F23414BQ36036190-B49A223C-FFB9-40D8-8253-FD383C64DBBFQ36050609-A39C50B4-34A3-4FA6-A59C-5C702E6D45B8Q36215326-2E4BEB86-7072-454D-B4BB-042E31DC333EQ36226940-EFB257D5-1046-4E5D-98AB-B001DF3F1DD1Q36688818-EAD55E84-713F-4E2E-BD38-1EEC2FE399E9Q37287759-956DCCFC-079D-41E3-A4F4-79D812ADF80CQ37440612-B33FEF8E-5DE3-454D-95B6-9E89E47250A9Q37576913-2BC86D6E-04A5-45E7-9FA1-3CD79172E303Q39167799-9562B206-F50E-43A4-99E3-5BA43B57AE29Q39261292-555DE36D-823C-466F-A3B2-780AC28CDC46Q39677650-01A8A06B-1AA0-449F-9821-4A6DBB18680DQ40069993-659CBFB6-5D71-48E5-9670-289BA14B227FQ40565317-C5E4AD5A-5971-43D4-9A72-7326648F4188Q42429426-7836E614-390D-4495-B8FA-C5418757D9BEQ45364383-D682BAA7-0C0E-4FFF-BB23-DBCE89A766AEQ47664266-C08C7017-FD87-4BD8-ABD3-AA4F41119E79Q47720458-69649C5E-C9AB-4113-8AAD-410085BD852E
P2860
Clinical outcomes after initial pseudomonas acquisition in cystic fibrosis.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh
2014年學術文章
@zh-hant
name
Clinical outcomes after initial pseudomonas acquisition in cystic fibrosis.
@en
Clinical outcomes after initial pseudomonas acquisition in cystic fibrosis.
@nl
type
label
Clinical outcomes after initial pseudomonas acquisition in cystic fibrosis.
@en
Clinical outcomes after initial pseudomonas acquisition in cystic fibrosis.
@nl
prefLabel
Clinical outcomes after initial pseudomonas acquisition in cystic fibrosis.
@en
Clinical outcomes after initial pseudomonas acquisition in cystic fibrosis.
@nl
P2093
P2860
P356
P1476
Clinical outcomes after initial pseudomonas acquisition in cystic fibrosis
@en
P2093
EPIC Study Group
Julia Emerson
Margaret Rosenfeld
Ronald L Gibson
Sharon McNamara
Valeria Thompson
Wayne Morgan
P2860
P356
10.1002/PPUL.23036
P577
2014-03-18T00:00:00Z